|
Featured 2021 Journal Article PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics eraRyder, Simon J., Love, Amanda J., Duncan, Emma L. and Pattison, David A. (2021). PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clinical Endocrinology, 95 (1), 13-28. doi: 10.1111/cen.14375 |
|
Featured 2021 Journal Article [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A. ... TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397 (10276), 797-804. doi: 10.1016/S0140-6736(21)00237-3 |
|
Featured 2021 Journal Article Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluationArnfield, Evyn G., Thomas, Paul A., Roberts, Matthew J., Pelecanos, Anita M., Ramsay, Stuart C., Lin, Charles Y., Latter, Melissa J., Garcia, Peter L. and Pattison, David A. (2021). Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 48 (13), 4495-4507. doi: 10.1007/s00259-021-05456-3 |
|
Featured 2019 Journal Article Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocolIravani, Amir, Solomon, Benjamin, Pattison, David A., Jackson, Price, Ravi Kumar, Aravind, Kong, Grace, Hofman, Michael S., Akhurst, Tim and Hicks, Rodney J. (2019). Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid, 29 (11), 1634-1645. doi: 10.1089/thy.2019.0143 |
|
Featured 2019 Journal Article Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CTPattison, David A., MacFarlane, Lisa L., Callahan, Jason, Kane, Emma L., Akhurst, Timothy and Hicks, Rodney J. (2019). Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. EJNMMI Research, 9 (1) 15, 15. doi: 10.1186/s13550-019-0480-2 |
|
Featured 2017 Journal Article 18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual InterpretationPattison, David A., Bozin, Michael, Gorelik, Alexandra, Hofman, Michael S., Hicks, Rodney J. and Skandarajah, Anita (2017). 18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. Journal of Nuclear Medicine, 59 (5), 749-755. doi: 10.2967/jnumed.117.198085 |
|
Featured 2017 Journal Article Molecular imaging in the investigation of hypoglycaemic syndromes and their managementPattison, David A. and Hicks, Rodney J. (2017). Molecular imaging in the investigation of hypoglycaemic syndromes and their management. Endocrine-Related Cancer, 24 (6), R203-R221. doi: 10.1530/erc-17-0005 |
|
2025 Journal Article 2388P Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trialHansen, A.R., Pattison, D.A., Gan, C.L., Goh, J.C.H., Ngai, S., Katchel, L., Holmes, I., Baker, S., Campbell, L., Brady, J., Santoro, P., Crumbaker, M., Baronet, M., Rose, S., Adamovich, A.A., Puttick, S., Kryza, T., Kuan, K., Karmann, A. and Wyld, D.K. (2025). 2388P Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial. Annals of Oncology, 36, S1298-S1299. doi: 10.1016/j.annonc.2025.08.3004 |
|
2025 Journal Article A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancerRoberts, Matthew J., Roberts, Natasha A., Pelecanos, Anita, Yaxley, John W., Harley, Simon J. D., Siriwardana, Amila R., Cullen, Karla, Prior, Marita, Lindsay, Karen, Vela, Ian, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David A. (2025). A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer. EJNMMI Research, 15 (1) 92, 92-1. doi: 10.1186/s13550-025-01265-z |
|
2025 Journal Article Peptide receptor radionuclide therapy in malignant insulinomaPattison, David A., Kong, Grace, Akhurst, Timothy, Burge, Matthew, Chiang, Cherie, Hofman, Michael S., Hung, Te-Jui, Love, Amanda, Michael, Michael, Okano, Satomi, Ravi Kumar, Aravind S., Sachithanandan, Nirupa, Wyld, David and Hicks, Rodney J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine-Related Cancer, 32 (6) e250018, 6. doi: 10.1530/erc-25-0018 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... Zhang, Alison Y. (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 2025 (8), 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST studyFielding, David, Sidhu, Calvin, Alkhater, Mahmoud, Alawami, Moayed, Kops, Stephan E P, van der Heijden, Erik H F M, Bashirzadeh, Farzad, Windsor, Morgan, Nixon, Elizabeth, Son, Jung Hwa, Ananda Setty, Niranjan, Pattison, David A, Fong, William, Bhatt, Manoj, Dhiantravan, Nattakorn, Ramsay, Stuart, Boots, Robert, Putt, Michael, Pratt, Gary, Bettington, Catherine, Francis, Roslyn, Thomas, Paul, Steinke, Karin and Thomas, Rajesh (2025). Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study. BMJ Open Respiratory Research, 12 (1) e002553, e002553. doi: 10.1136/bmjresp-2024-002553 |
|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Journal Article The global reading room: performing a ventilation-perfusion study in a patient with recent COVID-19Grady, Erin, Pattison, David A., Redman, Stewart and Satoh, Yoko (2025). The global reading room: performing a ventilation-perfusion study in a patient with recent COVID-19. American Journal of Roentgenology, 224 (2) e2431348, 1-2. doi: 10.2214/ajr.24.31348 |
|
2025 Journal Article A method for validating PET and SPECT cameras for quantitative clinical imaging trials using novel radionuclidesBailey, Dale L., Willowson, Kathy P., O’Keefe, Graeme, Goodman, Steven, Patford, Shaun, McGill, George, Pattison, David A. and Scott, Andrew M. (2025). A method for validating PET and SPECT cameras for quantitative clinical imaging trials using novel radionuclides. Journal of Nuclear Medicine, 66 (2), 315-322. doi: 10.2967/jnumed.124.268578 |
|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D and Stockler, Martin R (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2024 Journal Article Intra-individual comparisons of [18F]fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in prostate cancer patients across different disease states: new insights into disease heterogeneityMcGeorge, Stephen, Pattison, David A., Dhiantravan, Nattakorn, Thomas, Paul A., Yaxley, John W. and Roberts, Matthew J. (2024). Intra-individual comparisons of [18F]fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in prostate cancer patients across different disease states: new insights into disease heterogeneity. Uro, 5 (1), 1-11. doi: 10.3390/uro5010001 |
|
2024 Journal Article Successful Localization of Recurrent MEN-1-Associated Hyperparathyroidism With 18F-Fluorocholine PET/CTWootton, Elizabeth, Wong, Clement, Love, Amanda and Pattison, David A. (2024). Successful Localization of Recurrent MEN-1-Associated Hyperparathyroidism With 18F-Fluorocholine PET/CT. JCEM Case Reports, 2 (12) luae222, 1-2. doi: 10.1210/jcemcr/luae222 |
|
2024 Journal Article Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyAzad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P ... Ratnayake, L (2024). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25 (10), 1267-1276. doi: 10.1016/s1470-2045(24)00440-6 |
|
2024 Journal Article The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohortTariq, Arsalan, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Pelecanos, Anita, Gan, Chun Loo, Goh, Jeffrey C., Wong, David, McBean, Rhiannon, Marsh, Phillip, Goodman, Steven, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John W., Thomas, Paul, Pattison, David A. and Roberts, Matthew J. (2024). The role of prostate-specific membrane antigen positron emission tomography/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohort. European Urology Focus, 10 (5), 770-778. doi: 10.1016/j.euf.2023.12.004 |
